GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (NAS:OCX) » Definitions » Shiller PE Ratio

OncoCyte (OncoCyte) Shiller PE Ratio : (As of Jun. 12, 2024)

View and export this data going back to 2015. Start your Free Trial

What is OncoCyte Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation

OncoCyte Shiller PE Ratio Historical Data

The historical data trend for OncoCyte's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Shiller PE Ratio Chart

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoCyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoCyte's Shiller PE Ratio

For the Diagnostics & Research subindustry, OncoCyte's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoCyte's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where OncoCyte's Shiller PE Ratio falls into.

OncoCyte Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

OncoCyte's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, OncoCyte's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)

Current CPI (Mar. 2024) = 131.7762.

OncoCyte Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.326 0.000
201409 0.000 100.428 0.000
201412 -4.642 99.070 -6.174
201503 -4.217 99.621 -5.578
201506 -4.347 100.684 -5.689
201509 -1.903 100.392 -2.498
201512 -2.800 99.792 -3.697
201603 -2.400 100.470 -3.148
201606 -2.000 101.688 -2.592
201609 -2.000 101.861 -2.587
201612 -2.200 101.863 -2.846
201703 -3.200 102.862 -4.100
201706 -2.600 103.349 -3.315
201709 -4.400 104.136 -5.568
201712 -2.600 104.011 -3.294
201803 -2.400 105.290 -3.004
201806 -2.400 106.317 -2.975
201809 -1.400 106.507 -1.732
201812 -2.200 105.998 -2.735
201903 -1.600 107.251 -1.966
201906 -2.071 108.070 -2.525
201909 -2.000 108.329 -2.433
201912 -3.000 108.420 -3.646
202003 -2.600 108.902 -3.146
202006 -2.800 108.767 -3.392
202009 -2.000 109.815 -2.400
202012 -1.800 109.897 -2.158
202103 -1.000 111.754 -1.179
202106 -2.400 114.631 -2.759
202109 -3.000 115.734 -3.416
202112 -7.800 117.630 -8.738
202203 -2.200 121.301 -2.390
202206 -1.480 125.017 -1.560
202209 -1.620 125.227 -1.705
202212 -8.030 125.222 -8.450
202303 0.400 127.348 0.414
202306 -1.070 128.729 -1.095
202309 -0.810 129.860 -0.822
202312 -2.070 129.419 -2.108
202403 -1.130 131.776 -1.130

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

OncoCyte  (NAS:OCX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.

Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.

OncoCyte Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of OncoCyte's Shiller PE Ratio provided by Please click on the following links to see related term pages.

OncoCyte (OncoCyte) Business Description

Traded in Other Exchanges
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011